Quick Answer
BIOMARIN PHARMACEUTICAL INC reported Cash And Cash Equivalents At Carrying Value of $1.31 billion for the year ending 2025.
- BIOMARIN PHARMACEUTICAL INC showed an increase of +39.1% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from BIOMARIN PHARMACEUTICAL INC's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2007 to 2025 (19 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 19 years of available data (2007 to 2025), BIOMARIN PHARMACEUTICAL INC's Cash And Cash Equivalents At Carrying Value has grown by 474.4%.
- Historical annual values: Fiscal year 2025: $1.31 billion | Fiscal year 2024: $942.84 million | Fiscal year 2023: $755.13 million | Fiscal year 2022: $724.53 million | Fiscal year 2021: $587.28 million | Fiscal year 2020: $649.16 million | Fiscal year 2019: $437.45 million | Fiscal year 2018: $493.98 million | Fiscal year 2017: $598.03 million | Fiscal year 2016: $408.33 million | Fiscal year 2015: $397.04 million | Fiscal year 2014: $875.49 million | Fiscal year 2013: $568.78 million | Fiscal year 2012: $180.53 million | Fiscal year 2011: $46.27 million | Fiscal year 2010: $88.08 million | Fiscal year 2009: $167.17 million | Fiscal year 2008: $222.90 million | Fiscal year 2007: $228.34 million.
- Data sourced from SEC EDGAR public filings as of June 24, 2026.
Last verified: